- UID
- 10062044
- 热情
- 28621
- 人气
- 30185
- 主题
- 328
- 帖子
- 9413
- 精华
- 0
- 积分
- 34327
- 分享
- 0
- 记录
- 0
- 相册
- 1
- 好友
- 1
- 日志
- 0
- 在线时间
- 5332 小时
- 注册时间
- 2017-6-10
- 阅读权限
- 30
- 最后登录
- 2024-11-23
升级 71.64% - UID
- 10062044
- 热情
- 28621
- 人气
- 30185
- 主题
- 328
- 帖子
- 9413
- 精华
- 0
- 积分
- 34327
- 阅读权限
- 30
- 注册时间
- 2017-6-10
|
The Ministry of Health is unable to provide individual clinical advice.
We advise you to contact your primary health care provider or GP to discuss the vaccine in light of your individual health care needs.
Novavax (Nuvaxovid) - a two-dose protein subunit vaccine - has been provisionally approved by New Zealand medicines regulator Medsafe for adults 18 years and over.
Medsafe's approval is one step in the process for accessing a COVID-19 vaccine for use in New Zealand. Cabinet will consider advice from the Ministry of Health and the COVID-19 Vaccination Technical Advisory Group (CV TAG) on the use of Novavax in New Zealand as part of the COVID-19 immunisation programme. Following advice and pending Cabinet’s decision to use, officials are working with Novavax to establish delivery schedules.
If Cabinet does approve the use of the Novavax vaccine, we anticipate there would be public announcements to inform the public of this decision. We would advise you to monitor the Ministry of Health website for any further updates around this: https://www.health.govt.nz/
|
|